Understanding and targeting genetic changes in complex karyotype acute myeloid leukemia
Project 2: Defining and exploiting genetic dependencies in complex karyotype AML
This study is looking at a tough type of leukemia called complex karyotype acute myeloid leukemia (CK AML) to find out how its unique genetic changes affect treatment, with the goal of discovering new ways to help patients, especially those with issues related to the p53 gene.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10862893 on NIH RePORTER |
What this research studies
This research focuses on complex karyotype acute myeloid leukemia (CK AML), a type of leukemia characterized by multiple genetic abnormalities that lead to poor treatment outcomes. The team will analyze the genomes of CK AML samples using a novel technique called digital karyotyping to identify specific genetic changes. By correlating these genetic features with patient outcomes, they aim to develop new treatment strategies that target the unique characteristics of CK AML, particularly those related to the loss of the p53 tumor suppressor gene. The research includes creating models to test potential therapies that could reverse the effects of p53 loss and improve patient responses to treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with complex karyotype acute myeloid leukemia who have specific genetic abnormalities.
Not a fit: Patients with other forms of leukemia or those without the complex karyotype may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with complex karyotype acute myeloid leukemia.
How similar studies have performed: Previous research has shown promise in targeting genetic abnormalities in other types of leukemia, suggesting potential for success in this novel approach.
Where this research is happening
New York, United States
- Sloan-Kettering Inst Can Research — New York, United States (Active)
Researchers
- Principal investigator: Lowe, Scott W. — Sloan-Kettering Inst Can Research
- Study coordinator: Lowe, Scott W.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.